Month: July 2018
-
Challenges Seek Solutions for Chronic Diseases, Oral Drugs in Animals
Two new crowdsourcing competitions announced this week are seeking ideas on broadening the scope of drugs being developed for companion animals, and making drugs easier to give to pets and farm animals.
-
Drug Discovery System Designed to Identify Difficult Targets
A lab in the U.K. developed a system for discovering new therapies that identify therapy targets linked to enzymes, some found in neurodegenerative diseases, previously considered too difficult to address.
-
Launching A Cosmetics Brand Is Not As Easy As You Think
This article will draw your attention towards some of the essentials steps you need to take, and how much investment you’re going to require.
-
Experimental Drug Extends Survival, Reverses Inherited ALS Damage
An experimental drug designed to silence a protein associated with inherited forms of amyotrophic lateral sclerosis, or ALS, is shown in tests with lab rodents to extend survival and reverse some neuromuscular damage.
-
BASF, UC-Davis Partner on Human Milk Sugars
BASF and a research institute at University of California in Davis are investigating complex sugars found in human breast milk, and their role in maintaining healthy gut microbes.
-
Meds for Those Employee Headaches
It can’t be ignored that employees can cause or be part of the biggest headaches that you’ll face as a business owner.
-
Univ. Spin-Off Developing Myelin Disease Treatments Unveiled
A spin-off enterprise from Case Western Reserve University is developing therapies designed to restore the myelin sheath around nerve cells destroyed in multiple sclerosis and other neurological disorders.
-
GSK, 23andMe Ink Precision Meds Discovery Deal
Consumer genetics company 23andMe signed a 4-year agreement to help drug maker GlaxoSmithKline find more precise drug targets and recruit clinical trial participants likely to respond to treatments.
-
Enjoy Big Data Success With These Guidelines
It’s not rare to find a marketing executive poring over analytic software, trying to figure out who bounced and why.
-
Merck, Biopharma Partner on Cell-Free Immune System Therapies
Drug maker Merck is acquiring the rights to therapies for cancer and autoimmune disorders based on a technology for developing synthetic proteins from a process that bypasses live cells.